Skip to main content

Table 1 Correlations between miR-10b-3p expression and clinicopathological parameters of ESCC patients

From: Promoter hypomethylation mediated upregulation of MicroRNA-10b-3p targets FOXO3 to promote the progression of esophageal squamous cell carcinoma (ESCC)

Characteristics Training group (n = 93) Test group (n = 102)
Low (n = 21) High (n = 72) P Low (n = 27) High (n = 75) P
Gender
 Male 17 (22.1%) 60 (77.9%) 0.799 21 (25.0%) 63 (75.0%) 0.467
 Female 4 (25.0%) 12 (75.0%) 6 (33.3%) 12 (66.7%)
Age
  ≤ 60 6 (22.2%) 21 (77.8%) 0.958 8 (22.9%) 27 (77.1%) 0.550
 >60 15 (22.7%) 51 (77.3%) 19 (28.4%) 48 (71.6%)
Tumor size
 < 5 cm 10 (19.8%) 41 (80.4%) 0.450 20 (30.3%) 46 (69.7%) 0.235
  ≥ 5 cm 11 (26.2%) 31 (73.8%) 7 (19.4%) 29 (80.6%)
Tumor stagea
 T1+ T2 7 (31.8%) 15 (68.2%) 0.270 9 (39.1%) 14 (60.9%) 0.118
 T3+ T4 13 (20.3%) 51 (79.7%) 18 (22.8%) 61 (77.2%)
Histological grade
 Well/moderate 17 (23.0%) 57 (77.0%) 0.858 21 (25.3%) 62 (74.7%) 0.576
 Poor/NS 4 (21.1%) 15 (78.9%) 6 (31.6%) 13 (68.4%)
Lymph node metastasis
 Negative 17 (37.8%) 28 (62.2%) 0.001 20 (33.9%) 39 (66.1%) 0.046
 Positive 4 (8.3%) 44 (91.7%) 7 (16.3%) 36 (83.7%)
Clinical stagesa
 I + II 17 (35.4%) 31 (64.6%) 0.002 22 (37.9%) 36 (62.1%) 0.003
 III + IV 3 (7.5%) 37 (92.5%) 5 (11.4%) 39 (88.6%)
  1. aNumbers do not equal to the total number due to missing data